NURIX THERAPEUTICS IN

Nurix Therapeutics Announces Clearance of Investigational New Drug Application for NX-5948 Supporting Plans to Expand Enrollment to U.S. Clinical Sites

15 ديسمبر 2022 16:01:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting

12 ديسمبر 2022 17:30:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Announces Webcast to Review Data from its Phase 1 Clinical Trial of BTK Degrader, NX-2127, Presented at the 64th American Society of Hematology Annual Meeting

07 ديسمبر 2022 16:01:00 بحسب Nasdaq GlobeNewswire

Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and Successful Completion of DeTIL-0255 Phase 1 Safety Run-in

10 نوفمبر 2022 09:00:02 بحسب Nasdaq GlobeNewswire

Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Malignancies

10 نوفمبر 2022 09:00:01 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting

03 نوفمبر 2022 09:00:01 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

02 نوفمبر 2022 16:01:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit

26 أكتوبر 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at the 5th Annual Targeted Protein Degradation (TPD) Summit

19 أكتوبر 2022 09:00:01 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update

06 أكتوبر 2022 16:01:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Announces Six Poster Presentations at the Upcoming Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

05 أكتوبر 2022 08:00:02 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Appoints Leading Industry Strategist Edward C. Saltzman to its Board of Directors

14 سبتمبر 2022 16:01:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

31 أغسطس 2022 16:01:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer

03 أغسطس 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Announces $40 Million Registered Direct Offering

08 يوليو 2022 08:00:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Announces $55 Million Registered Direct Offering

07 يوليو 2022 17:03:06 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate Update

07 يوليو 2022 16:05:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Announces Clearance of Investigational New Drug Application For NX-1607 Supporting Plans to Expand Enrollment to U.S. Clinical Sites

30 يونيو 2022 08:00:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Will Present Trial in Progress Posters for Two Clinical Programs at the 2022 Annual European Hematology Association (EHA) Congress

10 يونيو 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Nurix Therapeutics Will Present Trial in Progress Posters for Three Clinical Programs at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

03 يونيو 2022 07:00:00 بحسب Nasdaq GlobeNewswire